Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.67 |
| ▸ | EIF4EBP1 | Q13541 | 6/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690361 | 0.81 | PTGDR2 (1.00) | PTGDR2EIF4EBP1 | |
| SCHEMBL1690335 | 0.79 | PTGDR2 (0.71) | PTGDR2EIF4EBP1P2RX1SLC22A12HSD17B3 | |
| SCHEMBL2112925 | 0.78 | PTGDR2 (0.63) | PTGDR2MAPTMRGPRX4 | |
| SCHEMBL20255669 | 0.75 | PTGDR2 (0.60) | PTGDR2EIF4EBP1MEN1LMNAMAPT | |
| SCHEMBL10344931 | 0.73 | PTGDR2 (0.58) | PTGDR2P2RX1MEN1LMNAMAPT | |
| SCHEMBL2111898 | 0.73 | PTGDR2 (0.56) | PTGDR2P2RX1MEN1LMNAMAPT | |
| SCHEMBL5431292 | 0.72 | PTGDR2 (0.62) | PTGDR2EIF4EBP1P2RX1MAPTXDH | |
| SCHEMBL22115305 | 0.71 | PTGDR2 (0.54) | PTGDR2P2RX1MEN1LMNAMAPT | |
| SCHEMBL29472205 | 0.71 | TDP1 (0.53) | MEN1LMNAMAPTKMT2AMRGPRX4 | |
| SCHEMBL11178796 | 0.71 | TDP1 (0.53) | MEN1LMNAMAPTKMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PTGDR2 438/4885EIF4EBP1 3414/4885P2RX1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.